This gene encodes activin A type II receptor. Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases.[7]
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Donaldson CJ, Mathews LS, Vale WW (May 1992). "Molecular cloning and binding properties of the human type II activin receptor". Biochem. Biophys. Res. Commun. 184 (1): 310–6. doi:10.1016/0006-291X(92)91194-U. PMID1314589.
^Bondestam J, Horelli-Kuitunen N, Hildén K, Ritvos O, Aaltonen J (April 2000). "Assignment of ACVR2 and ACVR2B the human activin receptor type II and IIB genes to chromosome bands 2q22.2-->q23.3 and 3p22 and the human follistatin gene (FST) to chromosome 5q11.2 by FISH". Cytogenet. Cell Genet. 87 (3–4): 219–20. doi:10.1159/000015429. PMID10702675. S2CID36135054.
^De Winter JP, De Vries CJ, Van Achterberg TA, Ameerun RF, Feijen A, Sugino H, De Waele P, Huylebroeck D, Verschueren K, Van Den Eijden-Van Raaij AJ (May 1996). "Truncated activin type II receptors inhibit bioactivity by the formation of heteromeric complexes with activin type I. receptors". Exp. Cell Res. 224 (2): 323–34. doi:10.1006/excr.1996.0142. PMID8612709.
^Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W (March 2000). "Betaglycan binds inhibin and can mediate functional antagonism of activin signalling". Nature. 404 (6776): 411–4. Bibcode:2000Natur.404..411L. doi:10.1038/35006129. PMID10746731. S2CID4393629.
^Tsuchida K, Nakatani M, Matsuzaki T, Yamakawa N, Liu Z, Bao Y, Arai KY, Murakami T, Takehara Y, Kurisaki A, Sugino H (October 2004). "Novel factors in regulation of activin signaling". Mol. Cell. Endocrinol. 225 (1–2): 1–8. doi:10.1016/j.mce.2004.02.006. PMID15451561. S2CID34666659.
Matzuk MM, Bradley A (1992). "Cloning of the human activin receptor cDNA reveals high evolutionary conservation". Biochim. Biophys. Acta. 1130 (1): 105–8. doi:10.1016/0167-4781(92)90472-C. PMID1311955.
Attisano L, Cárcamo J, Ventura F, Weis FM, Massagué J, Wrana JL (1993). "Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors". Cell. 75 (4): 671–80. doi:10.1016/0092-8674(93)90488-C. PMID8242742. S2CID25408172.
Peng C, Huang TH, Jeung EB, Donaldson CJ, Vale WW, Leung PC (1993). "Expression of the type II activin receptor gene in the human placenta". Endocrinology. 133 (6): 3046–9. doi:10.1210/endo.133.6.8243335. PMID8243335.
De Winter JP, De Vries CJ, Van Achterberg TA, Ameerun RF, Feijen A, Sugino H, De Waele P, Huylebroeck D, Verschueren K, Van Den Eijden-Van Raaij AJ (1996). "Truncated activin type II receptors inhibit bioactivity by the formation of heteromeric complexes with activin type I. receptors". Exp. Cell Res. 224 (2): 323–34. doi:10.1006/excr.1996.0142. PMID8612709.
Liu QY, Niranjan B, Gomes P, Gomm JJ, Davies D, Coombes RC, Buluwela L (1996). "Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells". Cancer Res. 56 (5): 1155–63. PMID8640777.
D'Abronzo FH, Swearingen B, Klibanski A, Alexander JM (1999). "Mutational analysis of activin/transforming growth factor-beta type I and type II receptor kinases in human pituitary tumors". J. Clin. Endocrinol. Metab. 84 (5): 1716–21. doi:10.1210/jcem.84.5.5704. PMID10323406.
Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, Kawabata M, Miyazono K, Imamura T (1999). "Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation". J. Cell Sci. 112 (20): 3519–27. doi:10.1242/jcs.112.20.3519. PMID10504300.